Surrozen (SRZN) Liabilities and Shareholders Equity (2020 - 2026)
Surrozen (SRZN) posted quarterly Liabilities and Shareholders Equity of $120.7 million for Q1 2026, up 5.12% year-over-year from $114.8 million in Q1 2025, and up 22.27% quarter-over-quarter from $98.7 million in Q4 2025.
Surrozen (SRZN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Surrozen's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $120.7 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 5.12% year-over-year to $120.7 million; the TTM figure through Mar 2026 stood at $416.2 million (up 62.34% YoY), while the FY2025 annual figure was $98.7 million, up 103.7% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $120.7 million, up from $98.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $120.7 million in Q1 2026, with the low at $36.7 million in Q1 2024.
- The 5-year median for Liabilities and Shareholders Equity is $89.4 million (2022), against an average of $79.4 million.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity slumped 50.52% in 2024, then surged 212.75% in 2025.
- Surrozen's Liabilities and Shareholders Equity stood at $89.4 million in 2022, then tumbled by 48.48% to $46.1 million in 2023, then climbed by 5.18% to $48.5 million in 2024, then jumped by 103.7% to $98.7 million in 2025, then increased by 22.27% to $120.7 million in 2026.
- Business Quant data shows SRZN's Liabilities and Shareholders Equity at $120.7 million in Q1 2026, $98.7 million in Q4 2025, and $94.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 115.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.61 Mn |
| Mar 31, 2026 | 120.71 Mn |
| Dec 31, 2025 | 98.73 Mn |
| Sep 30, 2025 | 94.05 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 114.83 Mn |
| Dec 31, 2024 | 48.47 Mn |
| Sep 30, 2024 | 48.00 Mn |
| Jun 30, 2024 | 45.07 Mn |
| Mar 31, 2024 | 36.72 Mn |
| Dec 31, 2023 | 46.08 Mn |
| Sep 30, 2023 | 53.97 Mn |
| Jun 30, 2023 | 64.00 Mn |
| Mar 31, 2023 | 74.20 Mn |
| Dec 31, 2022 | 89.44 Mn |
| Sep 30, 2022 | 91.43 Mn |
| Jun 30, 2022 | 104.13 Mn |
| Mar 31, 2022 | 117.66 Mn |
| Dec 31, 2021 | 137.17 Mn |
| Sep 30, 2021 | 150.64 Mn |